Japan’s market for schizophrenia treatment to double by 2022
Japan’s schizophrenia treatment market value will undergo significant growth over the coming decade, with revenues doubling from $700 million in 2012 to $1.4 billion by 2022, representing a compound annual growth rate (CAGR) of 7.74%.
A new report from research and consulting firm GlobalData states that out of the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan), Japan will experience the greatest expansion over the forecast period. It will be followed by the UK and French markets, which are expected to achieve CAGRs of 5.58% and 4.65%, respectively.
A key driver behind Japan’s schizophrenia market revenue growth will be the doubling of available therapy options between 2012 and 2022, which will offer patients greater autonomy, according to GlobalData.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze